ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the ...
Lacey Raymond, a licensed clinical social worker from Gower, Missouri, earned the prestigious Registered Play Therapist credential conferred by the Association for Play ...
Gemini Embedding 2 ships cross-modality retrieval with Matryoshka vectors, offering flexible dimensions for cost and accuracy tradeoffs.
This article explores how advanced immune imaging technologies enable real-time visualization of immune responses, improving ...
Pasqal, a global leader in neutral-atom quantum computing and member of the NVIDIA Inception program for startups, announced today the integration of the NVIDIA CUDA-Q platform ("CUDA-Q") with its ...
The new stadium-scale competition aims to give CrossFit athletes their own repeatable test of fitness ...
Leerink Global Healthcare Conference 2026 March 10, 2026 11:20 AM EDTCompany ParticipantsJason Garland - CFO & ...
Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer March 13, 2026 11:30 ...
Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA confirmed for Q3 2026Zipalertinib rolling NDA ...
G&A Expenses -- $13.8 million in the fourth quarter, of which $5.6 million was non-cash stock-based compensation; annual G&A ...
The PR House presents 10 Inspiring Women Personalities to Watch Out in 2026, celebrating impactful women across diverse fields.
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 Earnings Call Transcript March 12, 2026 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.17, expectations were $-0.22551.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results